Send to

Choose Destination
See comment in PubMed Commons below
Analyst. 2013 Sep 21;138(18):5404-10. doi: 10.1039/c3an00911d. Epub 2013 Jul 25.

On-chip screening for prostate cancer: an EIS microfluidic platform for contemporary detection of free and total PSA.

Author information

NNL Istituto Nanoscienze - CNR and Dipartimento di Matematica e Fisica Ennio De Giorgi, Università del Salento, Lecce, Italy.


Prostate cancer affects a large part of the western male population. The need for an early and accurate detection is thus a great challenge in common clinical practice, but the lack of specificity of the serum marker PSA (Prostate Specific Antigen) is a serious problem since its increased concentration can be related to several abnormalities. PSA, however, is found in serum in both a free and a complexed form with other proteins and the percentage amount of unbound PSA (the free-to-total PSA ratio) can be employed to distinguish prostate cancer from benign prostatic conditions, and also to predict the future risk of prostate cancer. To improve the operating characteristics of current PSA tests and to provide a clinical tool able to run label-free and sensitive analysis, we thus developed a biosensing platform based on Electrochemical Impedance Spectroscopy (EIS), which allows the contemporary detection of free and total PSA on a single biochip, enabling a quick screening for the risk of prostate cancer thanks to the presence of two different immobilized antibodies specific for the different antigens researched.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Royal Society of Chemistry
    Loading ...
    Support Center